drugset / Trial / NCT06460298
ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
Phase 1/2
Recruiting
51 enrolled
ProDa BioTech, LLC
Emory University · collabGeorgia State University · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase I/II Trial Evaluating the Safety and Efficacy of ProAgio, an anti- αvβ3 Integrin Cytotoxin, in Combination with Gemcitabine in Patients with Metastatic Triple Negative Breast Cancer
Timeline
- Start
- 2024-08-20
- Primary completion
- 2026-07-01
- Completion
- 2026-10-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ProAgio | Other / unclassified | — | Intravenous |
| Background | Gemcitabine | Small molecule | — | Intravenous |